A drug used in the last global mpox outbreak in 2022-23 is not effective against the more severe virus spreading rapidly in Africa, researchers have found.
The antiviral, tecovirimat, did not reduce the duration of lesions among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), according to the initial results of a placebo-controlled trial run by researchers in the DRC and the U.S.